Streetwise Medical Devices Articles


Firm Focused on Women's Health Posts 'Record' Sales of Treatment Device

  ()
A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts. read more >

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect. read more >

Analysts Say Medical Device Firm Sees Record Quarterly Revenue Growth, 120% YOY

  ()
Following the company's release of its latest financial report, three analysts weighed in on the results. read more >

Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY

Research Report
  ()
Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system. read more >

Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market

  ()
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. read more >

Maxim Raises Target Price of Biotech Company

Research Report
  ()
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech. read more >

Loan Provides Driver for Growth for Medical Device Firm

Research Report
  ()
Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth. read more >

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter

Source:   ()
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. read more >

Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth

Source: The Life Sciences Report  (02/22/2017)
Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. read more >

Luminor Drives the Scout DS Forward

Contributed Opinion
Source: Bob Moriarty for The Life Sciences Report  (02/06/2017)
Luminor Drives the Scout DS Forward
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. read more >

Companies Flocking to Japan for Biotech Deals

Source: Colin Lee Novick for The Life Sciences Report  (02/01/2017)
Companies Flocking to Japan for Biotech Deals
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. read more >

Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries

Source: The Life Sciences Report  (12/21/2016)
Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. read more >

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition

Source: The Life Sciences Report  (10/05/2016)
Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function. read more >

Imagin, a Better Way to Detect Bladder Cancer

Contributed Opinion
Source: Bob Moriarty for The Life Sciences Report  (09/20/2016)
Imagin, a Better Way to Detect Bladder Cancer
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. read more >

The ASX: Investing in an Emerging Biotech Frontier

Contributed Opinion
Source: Stuart Roberts for The Life Sciences Report  (08/10/2016)
The ASX: Investing in an Emerging Biotech Frontier
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. read more >

How Sick Will Brexit Make Biotech and Pharma?

Source: Tracy Salcedo of The Life Sciences Report  (06/29/2016)
How Sick Will Brexit Make Biotech and Pharma?
Given the uncertainty and dire economic forecasts following the Brexit vote, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. read more >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

Source: George S. Mack of The Life Sciences Report  (05/11/2016)
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Unmet medical needs exist all over the globe, creating a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare analyst Dennis Hulme of Edison Investment Research cites a group of Australian medtech and biotech names that investors should look at very carefully. read more >
Management Q&A: View from the Top

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (03/29/2016)
Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview, Moseda CEO Dr. Lisa Crossley describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home while reducing the cost of care. read more >

Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma

Source: George S. Mack of The Life Sciences Report  (02/17/2016)
Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma
The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. Wijma applies his small-cap expertise to shed light on overlooked biotechs from Canada, Europe and Australia that could bring huge returns to investor portfolios. read more >

Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell

Source: George S. Mack of The Life Sciences Report  (02/03/2016)
Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Canada encompasses healthcare-related businesses that are generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios: He knows both spheres, and as a hedge fund and mutual fund manager he has made a specialty in acquisitions of cash-generating healthcare companies. read more >
Management Q&A: View from the Top

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

Managment Q&A: View from the Top
Source: Peter Byrne of The Life Sciences Report  (02/03/2016)
Stewart Washer
In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. read more >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase

Source: Tracy Salcedo of The Life Sciences Report  (01/27/2016)
The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. read more >

Rick Mills: How to Profit from the Demands of a Growing World Population

Source: JT Long of The Gold Report  (01/21/2016)
Rick Mills: How to Profit from the Demands of a Growing World Population
As the world prepares to house, feed and care for 9.7 billion people, Ahead of the Herd founder Rick Mills is looking for the companies that will profit from the silent tsunami of demand creeping up on resource and healthcare providers. read more >

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News

Source: George S. Mack of The Life Sciences Report  (01/20/2016)
The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News
Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. read more >

A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe

Source: Staff of The Life Sciences Report  (01/13/2016)
A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe
Canadian healthcare stocks offer a windbreak for biotech investors in a turbulent market, especially if they select a diversified basket across the various sectors, says Euro Pacific Canada's Doug Loe. read more >
Showing Results: 1 to 25 of 32 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

More Experts